Jan 20, 20212 min
$XBI $154.22 (+1.64%) 📈
COVID:
$GRTS (+248.51%) - Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
$NK (+6.32%) - ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread
PIPELINE:
$ACRS (+220.24%) - Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
$CYAD (+6.52%) - Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD101 in mCRC at ASCO-GI Symposium
https://celyad.com/wp-content/uploads/2021/01/Celyad-Oncology-ASCO-GI-2021_Press-Release-_EN.pdf
$ACRX (+12.98%) - AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen
$CCCC (+3.18%) - C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
$COCP (+45.03%) - Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
https://ir.cocrystalpharma.com/press-releases/detail/109
$DTIL (+29.56%) - Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
$MCRB (+1.96%) - Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium
$MTEM (+6.70%) - Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology
$MTCR (+5.67%) - Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH
$OMER (+7.75%) - Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
$PHAT (2.64%) - Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
$PIRS (+0.38%) - FDA Lifts Partial Clinical Hold On PRS-343 Phase 1 Studies
https://ir.pieris.com/press-releases/detail/652
$RYTM (-0.55%) - Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts
$TCON (+3.93%) - TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
$XBIT (+1.59%) - XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
FINANCIAL:
$ADMA (+8.74%) - ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook
$MRUS (+6.01%) - Merus N.V. Announces Proposed Public Offering of Common Shares
$NERV (+27.31%) - Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
$EDIT (+5.29%) - Editas Medicine Announces Offering Of Common Stock
$ACRX (+12.98%) - AcelRx Announces Underwritten Public Offering of Common Stock
$ACRS (+220.24%) - Aclaris Announces Proposed Public Offering of Common Stock
$FULC (+6.64%) - Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
$SYRS (+6.03%) - Syros Announces Proposed Offering of Common Stock
https://ir.syros.com/press-releases/detail/211/syros-announces-proposed-offering-of-common-stock
$ONCS (-3.04%) - OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™